QUOTE AND NEWS
PR Newswire  Jan 25  Comment 
BRAINTREE, Mass. and LONDON, Jan. 25 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that the Oxford Radcliffe Hospital Trust was named the winner of the best Public Sector Project at the UK IT Computing Awards. The
PR Newswire  Jan 12  Comment 
BRAINTREE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) will announce its Q3FY10 earnings on February 1, 2010 in a pre-market press release and 10:00 am (EST) webcast. Webcast Link:
PR Newswire  Jan 4  Comment 
BRAINTREE, Mass., Jan. 4/PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that Brian Concannon, Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2010 at
Stock Blog Hub  Dec 16  Comment 
Haemonetics Corporation (HAE) has recently filed a new lawsuit against Fenwal Inc. regarding the latter’s continued patent infringement with the release of its red cell collection kits. Fenwal allegedly modified its separation chamber to bypass...
PR Newswire  Dec 15  Comment 
LAKE ZURICH, Ill., Dec. 15 /PRNewswire/ -- Fenwal Inc., a global leader focused on improving blood collection, safety and availability for patient care, reiterated its commitment to provide blood centers with Alyx® system supplies needed to collect
PR Newswire  Dec 14  Comment 
BRAINTREE, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that it has filed a new legal action to stop Fenwal Inc.'s continued patent infringement resulting from Fenwal's just released red cell collection
MedPage Today  Dec 2  Comment 
WASHINGTON (MedPage Today) -- The FDA has approved ecallantide (Kalbitor), the first subcutaneous treatment for acute hereditary angioedema (HAE) attacks, for patients 16 and older.
MedPage Today  Nov 10  Comment 
MIAMI BEACH (MedPage Today) -- An investigational kallikrein inhibitor may hold out hope for people with acute attacks of hereditary angioedema (HAE), a researcher said here.
TheStreet.com  Nov 9  Comment 
Haemonetics makes products that are changing the way blood is collected, stored and donated.
Stock Blog Hub  Nov 4  Comment 
Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents. Sales Total revenues in...



Thank you for your suggestion
 
TOP CONTRIBUTORS
HAE AT A GLANCE
 
 
 
 
 
 
 
 

Haemonetics was founded in 1971 and became publicly owned in 1979. A division of American Hospital Supply Corporation, and then DuPont in 1985, the company completed its Initial Public Offering in 1991, with Du Pont divesting its remaining interest. The company is the market leader in developing and manufacturing blood collection and processing technology to help ensure a safe and adequate blood supply. The company manufactures automated systems and single use consumables used in blood donation, blood processing, and surgical salvage of blood. Haemonetics' customers are blood banks and plasma collectors, hospitals and hospital service providers. The American Red Cross is its largest customer. In 2004, the company reorganized into two product groups to address the blood donor and surgical patient markets. In Donor Products, the company offers automated plasma and platelet collection systems, as well as processing systems to freeze, thaw and wash red blood cells. The company also contract manufactures sterile I.V. solutions for pharmaceutical customers. In Patient Products, the company offers surgical blood salvage systems that are used to collect the patient's own blood that is then reused rather than lost. Haemonetics also markets data management systems through their 5D Information Systems subsidiary to promote efficient and compliant operations of blood collection vendors. The company operates in the U.S., Europe and Asia, including Japan. Haemonetics markets its products in more than 50 countries, using a direct sales force as well as some independent distributors, totaling 1,826 full time employees. In fiscal 2007, the company generated $449.6 million in revenues, with roughly 43% of revenues generated in the U.S. and the remainder internationally. Principally, Japan accounted for about 20% of fiscal 2007 revenues and Europe contributed about 28% to fiscal 2007 revenues.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki